您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Tazobactam(sodium salt)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tazobactam(sodium salt)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tazobactam(sodium salt)图片
CAS NO:89785-84-2
规格:98%
分子量:322.3
包装与价格:
包装价格(元)
250mg电议
500mg电议
1g电议

产品介绍
β-lactamases inhibitor
CAS:89785-84-2
分子式:C10H11N4O5S ? Na
分子量:322.3
纯度:98%
存储:Store at -20°C

Background:

Tazobactam is a β-lactamase inhibitor [1]. Tazobactam shows intrinsic activity against Acinetobacter strains.


The β-Lactamases are responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome β-lactamase-mediated resistance, β-lactamase inhibitors have been introduced into clinical practice [2].


Tazobactam alone showed an MIC of ≤ 8 mg/liter (range 2 to 32 mg/liter) against 29 of the 38 strains [1]. Tazobactam in combination with the ureidopenicillin, piperacillin successfully restored the activity of piperacillin against β-lactamase-producing bacteria [3]. Tazobactam exhibited inhibitory activity and protected piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases [3]. Tazobactam showed species-specific activity against class I chromosomally-mediated enzymes [3].


Preliminary clinical data indicated that the fixed combination of piperacillin /tazobactam was effective in the treatment of moderate to severe polymicrobial infections, including skin, intra-abdominal and soft-tissue and lower respiratory tract infections [3]. Piperacillin/tazobactam in combination with an aminoglycoside was effective in the empirical treatment of fever in patients with neutropenia. In phase III trials, piperacillin/tazobactam showed a tolerability profile typical of a penicillin agent [3].


参考文献:
[1] Higgins P G, Wisplinghoff H, Stefanik D, et al.  In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains[J]. Antimicrobial agents and chemotherapy, 2004, 48(5): 1586-1592.
[2] Drawz S M, Bonomo R A.  Three decades of β-lactamase inhibitors[J]. Clinical microbiology reviews, 2010, 23(1): 160-201.
[3] Perry C M, Markham A.  Piperacillin/tazobactam[J]. Drugs, 1999, 57(5): 805-843.